?Upadacitinib Intermediate (CAS 1310726-60-3) | GMP-Certified API Precursor for JAK Inhibitor & Autoimmune Drug Synthesis?

?Overview?

Upadacitinib Intermediate is a ?pharmaceutical-grade chemical building block? critical for synthesizing ?Upadacitinib (Rinvoq?)?—a FDA-approved JAK1 inhibitor targeting ?rheumatoid arthritis, psoriasis, and ulcerative colitis??13. With ≥99% purity (validated by GC-MS/HPLC), it complies with ?USP/EP standards? for API manufacturing and clinical trial material preparation?14.

?Key Applications?

?? ?Drug Development?:

• Core precursor for 

  ?JAK1 inhibitor optimization?

  , enhancing therapeutic efficacy in autoimmune and inflammatory diseases?34.

• Supports 

  ?Rinvoq? generics R&D?

   and novel drug formulations?14.

?? ?Industrial Use?:

• Scalable synthesis under 

  ?GMP guidelines?

   for bulk API production?45.

?Product Specifications?

? ?Purity?: ≥99% (COA provided; residual solvents <30 ppm)?45.
? ?Form?: White crystalline powder with solubility in DMSO and ethanol?14.
?? ?Packaging?: Custom options (1 kg to 50 kg) with nitrogen-sealed containers for stability?45.
??? ?Storage?: 24-month shelf life at -20°C in moisture-proof packaging?15.

?Quality Assurance?

?? ?GMP Compliance?: Manufactured in ISO-certified facilities with batch-specific traceability?45.
?? ?Analytical Support?: Includes chiral purity, heavy metals (<5 ppm), and microbial limit testing?46.

?Supply Advantages?

?? ?Global Stock?: Available in US, EU, and APAC warehouses for expedited shipping?15.
??? ?Tailored Services?: Technical documentation (EDMF, CMC) and regulatory support?45.

?Keywords?: Upadacitinib Intermediate CAS 1310726-60-3, JAK Inhibitor Synthesis, Autoimmune Drug Development, GMP Pharmaceutical Intermediates, Rheumatoid Arthritis API Precursors?13.